Overview

A Study for Participants With Recurrent or Metastatic Squamous Cell Head and Neck Cancer

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to look for an improvement in progression free survival with the combination of pemetrexed, carboplatin (or cisplatin) and cetuximab in participants with recurrent or metastatic squamous cell carcinoma of the head and neck.
Phase:
Phase 2
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Carboplatin
Cetuximab
Cisplatin
Pemetrexed